Podcasts about IDE

We often look for ways to reduce the load on our brains, seeking shortcuts and optimizations to get ahead. Sometimes this works, reinforcing the belief that we can hack our way around every problem. However, this episode addresses the truth that many fundamental aspects of your career require something difficult, messy, slow, or inefficient, demanding deep thought and repeated failure.This episode details the difficult truths about facing the most essential challenges in your career:Understand the Hard Path: Recognize that many aspects of your career, skill set, relationships, and hobbies require something difficult, messy, slow, or inefficient, demanding deep thought and repeated failure.Identify Your Primary Obstacles: Pinpoint the hard things you are procrastinating on, such as developing essential domain knowledge, deepening relationships with crucial co-workers or your manager, or getting the necessary "reps" of difficult building and practice.The Path to Mastery: Realize that becoming a great engineer (e.g., a great Python developer) is achieved not by reading books or finding perfect tools, but by building things over and over. This practice includes receiving feedback from peers and applying what you learn under challenge.The Pain of Decision: Explore why it is difficult to even decide to do a hard thing. By committing to the challenging path, you are choosing to cut off your optionality and giving up the hope of finding an easier, lower-investment alternative.Sustaining Commitment: Understand that initial motivation or an energetic feeling will not carry you through the obstacle when the development process becomes awkward, slow, or frustrating. Staying committed requires reinforcing your core underlying reason for doing the hard work.The Reward: Recognize that if you successfully address the hard thing you know needs doing, everything else in your life and career becomes easier.

Topics covered in this episode: Advent of Code starts today Django 6 is coming Advanced, Overlooked Python Typing codespell Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Brian #1: Advent of Code starts today A few changes, like 12 days this year, which honestly, I'm grateful for. See also: elf: Advent of Code CLI helper for Python Michael #2: Django 6 is coming Expected December 2025 Django 6.0 supports Python 3.12, 3.13, and 3.14 Built-in support for the Content Security Policy (CSP) standard is now available, making it easier to protect web applications against content injection attacks such as cross-site scripting (XSS). The Django Template Language now supports template partials, making it easier to encapsulate and reuse small named fragments within a template file. Django now includes a built-in Tasks framework for running code outside the HTTP request–response cycle. This enables offloading work, such as sending emails or processing data, to background workers. Email handling in Django now uses Python's modern email API, introduced in Python 3.6. This API, centered around the email.message.EmailMessage class Brian #3: Advanced, Overlooked Python Typing get_args, TypeGuard, TypeIs, and more goodies Michael #4: codespell Learned from this PR for the Talk Python book. Fix common misspellings in text files. It's designed primarily for checking misspelled words in source code (backslash escapes are skipped), but it can be used with other files as well. It does not check for word membership in a complete dictionary, but instead looks for a set of common misspellings. Therefore it should catch errors like "adn", but it will not catch "adnasdfasdf". It shouldn't generate false-positives when you use a niche term it doesn't know about. Extras Brian: Is mkdocs maintained? Hatch 1.16 Michael: Follow up on tach from Gerben Dekker: tach has been unmaintained for a bit but is not anymore. It was the main product from Gauge which is a Y combinator startup that pivoted to something unrelated and abandoned tach. However, https://github.com/DetachHead forked it but now got access to the main repo and has committed to maintaining it. ruff analyze graph is fully independent of tach - we actually started to look into alternatives for tach when it became unmaintained and then found ruff analyze graph. For our use case, with just a bit of manipulation on top of ruff analyze graph we replaced our use of deptry (which was slower - and I try to be careful depending on one-man projects). A Review of Michael Kennedy's book, “Talk Python in Production” - Thanks Doug Joke: NoaaS

On this episode I sit down with indie app builder and designer Chris ****Raroque to walk through his real AI coding workflow. Chris explains how he ships a portfolio of productivity apps doing thousands in MRR by pairing Claude Code and Cursor instead of picking just one tool. He live-demos “vibe coding” an iOS animation, then compares how Claude Code and Cursor's plan mode tackle the same task. The episode closes with concrete tips on plan mode, MCP servers, AI code review, dictation, and deep research so solo devs can build bigger apps than they could alone. Timestamps 00:00 – Intro 03:04 – Which Tools & Models to Use 09:16 – Thoughts on the Vibe Coding Mobile App Landscape 11:14 – Live demo: prompting Claude Code to build an iOS “AI searching” animation 18:07 – Live demo: prompting Cursor with same task 21:02 – Chris's Best Tips for Vibe Coders Key Points You don't have to pick one IDE copilot: Chris actively switches between Claude Code and Cursor because they have different strengths. For very complex bug-hunting, he prefers Cursor with plan mode; for big-picture app architecture, he leans on Claude Code with Opus. Non-developers should start on higher-level “vibe coding” platforms like Create Anything for mobile apps before graduating to Claude/Cursor. Plan mode plus detailed, spoken prompts dramatically improves code quality, especially for UI and animation work. MCP servers and AI code review bots let solo developers safely set up infra, enforce security, and catch bugs they'd otherwise miss. Claude's deep research is a powerful way to choose the right patterns and libraries before handing implementation back to Claude Code or Cursor. The #1 tool to find startup ideas/trends - https://www.ideabrowser.com LCA helps Fortune 500s and fast-growing startups build their future - from Warner Music to Fortnite to Dropbox. We turn 'what if' into reality with AI, apps, and next-gen products https://latecheckout.agency/ The Vibe Marketer - Resources for people into vibe marketing/marketing with AI: thevibemarketer.com Startup Empire - get your free builders toolkit to build cashflowing business - https://startup-ideas-pod.link/startup-empire-toolkit Become a member - https://startup-ideas-pod.link/startup-empire FIND ME ON SOCIAL X/Twitter: https://twitter.com/gregisenberg Instagram: https://instagram.com/gregisenberg/ LinkedIn: https://www.linkedin.com/in/gisenberg/ FIND CHRIS ON SOCIAL Youtube: https://www.youtube.com/@raroque X/Twitter: https://x.com/raroque Instagram: https://www.instagram.com/chris.raroque/

Cette semaine, Google a appuyé sur le bouton rouge !

In this episode, I'm talking with Vincent Warmerdam about treating LLMs as just another API in your Python app, with clear boundaries, small focused endpoints, and good monitoring. We'll dig into patterns for wrapping these calls, caching and inspecting responses, and deciding where an LLM API actually earns its keep in your architecture. Episode sponsors Seer: AI Debugging, Code TALKPYTHON NordStellar Talk Python Courses Links from the show Vincent on X: @fishnets88 Vincent on Mastodon: @koaning LLM Building Blocks for Python Co-urse: training.talkpython.fm Top Talk Python Episodes of 2024: talkpython.fm LLM Usage - Datasette: llm.datasette.io DiskCache - Disk Backed Cache (Documentation): grantjenks.com smartfunc - Turn docstrings into LLM-functions: github.com Ollama: ollama.com LM Studio - Local AI: lmstudio.ai marimo - A Next-Generation Python Notebook: marimo.io Pydantic: pydantic.dev Instructor - Complex Schemas & Validation (Python): python.useinstructor.com Diving into PydanticAI with marimo: youtube.com Cline - AI Coding Agent: cline.bot OpenRouter - The Unified Interface For LLMs: openrouter.ai Leafcloud: leaf.cloud OpenAI looks for its "Google Chrome" moment with new Atlas web browser: arstechnica.com Watch this episode on YouTube: youtube.com Episode #528 deep-dive: talkpython.fm/528 Episode transcripts: talkpython.fm Theme Song: Developer Rap

Jozef Banáš otvorene o aktuálnej dobe. (❤ INFO: Podujatia - https://www.40plus.sk/podujatia-odznova/ ❤ Info o overených vychytávkach z podcastu LINK - https://www.40plus.sk/vychytavky/ )Keď človek niečo chce, nič ho nezastaví!Proti prúdu. S prúdom ísť neviem. Možno ma nebudú mať radi. Ale koho z rebelov mali radi? Aj toto boli slová jednej z najznámejších spisovateliek všetkých čias, keď sa vydala na cestu písania. Rebelka Timrava. A presne na témy rebelstva, prúdu, protiprúdov sa cez posolstvá Timravy budem rozprávať s mojim hosťom, ktorým je spisovateľ, ale aj rebel, Jozef Banáš. Ďakujem, že ste tu so mnou a podporujete moju tvorbu. Aj vďaka tomu môžem tu i tam točiť už v štúdiu. Tentokrát díky Marekovi Kulhánkovi*********************************************************Ďakujem, že ma podporujete na Herohero alebo tu na YouTube. Aj vďaka vám vzniká tento obsah. Chcete ma začať podporovať? Info tu: https://herohero.co/odznova Podpora je možná aj tu na YouTube.. zmysel to pre má od 5,99€ (50% z vášho predplatného mi zoberie YouTube ako províziu. Tak si to viete spočítať...Hero berie len 12,5%) Predplatné 2,99 na YT je bez nároku na obsah vopred. Ide len o sympatizovanie, za čo ďakujem... Ak nechcete platiť kartou, možné je podporovať aj cez číslo účtu o. z. : SK45 8330 0000 0022 0165 1060 - do poznámky uveďte, že ide o DAR ĎAKUJEM a nezabudnite pozrieť info a linky o podujatiach a vychytávkach ... ( ❤INFO: Podujatia - https://www.40plus.sk/podujatia-odznova/ ❤Info o overených vychytávkach z podcastu LINK - https://www.40plus.sk/vychytavky/ ) Buďte zdraví Martina Valachová

Psí sporty nejsou jen o agility. Existují desítky různých variací psích sportů. Podle zkušených chovatelek z Agility Sezemice se pes při správném vedení naučí každý sport. Ideální je vybrat si ten, který k psovi i pánovi nejlépe sedne.

Psí sporty nejsou jen o agility. Existují desítky různých variací psích sportů. Podle zkušených chovatelek z Agility Sezemice se pes při správném vedení naučí každý sport. Ideální je vybrat si ten, který k psovi i pánovi nejlépe sedne.

Santo Espírito (parte 14) - Shaila Manzoni by IDE

Psí sporty nejsou jen o agility. Existují desítky různých variací psích sportů. Podle zkušených chovatelek z Agility Sezemice se pes při správném vedení naučí každý sport. Ideální je vybrat si ten, který k psovi i pánovi nejlépe sedne.

Psí sporty nejsou jen o agility. Existují desítky různých variací psích sportů. Podle zkušených chovatelek z Agility Sezemice se pes při správném vedení naučí každý sport. Ideální je vybrat si ten, který k psovi i pánovi nejlépe sedne.

Psí sporty nejsou jen o agility. Existují desítky různých variací psích sportů. Podle zkušených chovatelek z Agility Sezemice se pes při správném vedení naučí každý sport. Ideální je vybrat si ten, který k psovi i pánovi nejlépe sedne.

Psí sporty nejsou jen o agility. Existují desítky různých variací psích sportů. Podle zkušených chovatelek z Agility Sezemice se pes při správném vedení naučí každý sport. Ideální je vybrat si ten, který k psovi i pánovi nejlépe sedne.

Psí sporty nejsou jen o agility. Existují desítky různých variací psích sportů. Podle zkušených chovatelek z Agility Sezemice se pes při správném vedení naučí každý sport. Ideální je vybrat si ten, který k psovi i pánovi nejlépe sedne.

Psí sporty nejsou jen o agility. Existují desítky různých variací psích sportů. Podle zkušených chovatelek z Agility Sezemice se pes při správném vedení naučí každý sport. Ideální je vybrat si ten, který k psovi i pánovi nejlépe sedne.

Psí sporty nejsou jen o agility. Existují desítky různých variací psích sportů. Podle zkušených chovatelek z Agility Sezemice se pes při správném vedení naučí každý sport. Ideální je vybrat si ten, který k psovi i pánovi nejlépe sedne.

Psí sporty nejsou jen o agility. Existují desítky různých variací psích sportů. Podle zkušených chovatelek z Agility Sezemice se pes při správném vedení naučí každý sport. Ideální je vybrat si ten, který k psovi i pánovi nejlépe sedne.

Psí sporty nejsou jen o agility. Existují desítky různých variací psích sportů. Podle zkušených chovatelek z Agility Sezemice se pes při správném vedení naučí každý sport. Ideální je vybrat si ten, který k psovi i pánovi nejlépe sedne.

Psí sporty nejsou jen o agility. Existují desítky různých variací psích sportů. Podle zkušených chovatelek z Agility Sezemice se pes při správném vedení naučí každý sport. Ideální je vybrat si ten, který k psovi i pánovi nejlépe sedne.

„Demokracia funguje práve na nezávislých inštitúciách. Dobre spravovaný štát funguje na ľuďoch, ktorí sú odborníci,“ hovorí politológ Radoslav Štefančík. Reaguje tak na snahu vládnej väčšiny zrušiť úrad na ochranu oznamovateľov korupcie. „Ide im o vlastnú beztrestnosť, o svoje pohodlie, pretože vidia, že spravodlivosť, aj keď je niekedy pomalá, nakoniec príde,“ hovorí politológ. „Problém je však v tom, a nespravodliví ľudia to vedia, že sú niektorí, ktorí sa nenechajú podplatiť, ktorí sa nenechajú vydierať, a práve takíto čestní ľudia podvodníkom vadia.“Vládna väčšina dokonáva rušenie Úradu pre oznamovateľov korupcie. Paradoxne toho úradu, ktorý Peter Pellegrini a jeho Matúš Šutaj Eštok svojho času zakladali. Sama hovorí, že nejde o rušenie, ale jeho transformáciu, naviac s rozšírením záberu – ochranu oznamovateľov korupcie má rozšíriť o ochranu obetí trestných činov. Opozícia oponuje Eštokovou pomstou za Čurillovcov, pre ktorých rezort obrany dostal stotisícovú pokutu. Minister totiž na nich siahol bez ohľadu na to, že boli pod ochranou úradu. Proti kroku vlády sa ozvali výrazné tváre justície, mimovládneho sektora a vytiahli pred parlament rozhorčených ľudí.Odchádzajúci týždeň však bol aj o nahnevanom Andrejovi Dankovi, ktorý odmieta vstúpiť na úrad vlády, kým tam je premiérov poradca pošpinený Epsteinovimi zoznamami; o novej vojne v prokuratúre – medzi Marošom Žilinkom a žilinským krajským prokurátorom Tomášom Baloghom; či o opäť nespokojnom poslancovi Ferenčákovi, ktorý sa má vzdať postu šéfa parlamentného výboru, aby ho mohol nahradiť bývalý vicepremiér Peter Kmec pre spornú dotačnú výzvu.Čo napovedal tento týždeň o krajine, kde sa rodí stále menej detí a tie, čo tu zostávajú, si aj od premiéra vypočujú, že „za marišku namaľujú, čo chcú“ – to v narážke na popradského študenta Mura a jeho kriedovú revolúciu.Na krajinu posledného týždňa sa pozrieme s politológom Radoslavom Štefančíkom. „Táto moc sa bojí zdravých a silných inštitúcií,“ hovorí. „Prekážajú jej čestní odborníci,“ dodáva.Podcast pripravil Jaroslav Barborák.

Celovečerni prvenec Ester Ivakič, Ida, ki je pela tako grdo, da so še mrtvi vstali od mrtvih in zapeli z njo, delno nadaljuje izrazito domišljijsko, igrivo in hkrati surovo estetiko, ki jo je režiserka začrtala v svojih kratkih, sicer veliko bolj eksperimentalnih filmih, s katerimi je pokazala, da jo že lahko uvrščamo med najbolj samosvoje in prepoznavne ustvarjalce pri nas. Priredba zbirke kratkih zgodb Noben glas Suzane Tratnik, ki sta jo Ester Ivakič in scenaristka Nika Jurman za film nekoliko preoblikovali, ohranja geografski in delno časovni okvir prekmurskega podeželja konec 20. stoletja, vendar ga ne uporablja povsem kot realistično kuliso, temveč tudi kot polje za senzorično in asociativno pripoved. Ida odrašča v tesnem družinskem krogu: s staro mamo slabega zdravja, očetom, ki – kot je pregovorno značilno za slovensko podeželje – v nedogled gradi novo hišo, in mamo, katere preteklost je prežeta s temnejšimi toni. Ido – kot je morda pri otrocih njene starosti pogosto – nedoumljivost smrti hkrati privlači in plaši, vse močnejša je tudi slutnja, da bo prav stara mama prva, ki jo bo izgubila. Osrednji motiv izgube je prisoten na več ravneh, vendar film v tem smislu ne stremi k enotnemu emocionalnemu vrhuncu. Izguba se namesto tega pojavlja kot niz razpok v otroškem svetu domišljije in hkrati kot neizgovorjena konstanta sveta. Ta razpršenost postane logičen del poetike, ki raje vzpostavlja občutke kot dramske poudarke. Filmu se občasno pozna epizodičnost literarne predloge: posamezni motivi so izjemno močni, toda med njimi ni vedno popolne kohezije. Subtilni kvirovski podtoni iz kratkih zgodb o deklici, ki se začne zavedati svoje drugačnosti od okolja, v katerem odrašča, v filmu izginejo, to pa bi morda zlahka speljali na samocenzuro ali heteronormativizacijo pripovedi, vendar se zdi, da je odločitev delno tudi simptomatična za polje režiserkinega zanimanja: osredinjenje na fantastični, delno nadrealistični register ter zasledovanje čustvene in senzorične logike prizorov, ne pa psihološke ali identitetne strukture likov. Najizrazitejši intervencijski moment filma je v tem smislu uvedba magičnorealističnega motiva, utelešenega v žalobni, neopredeljivi navzočnosti sester Idine mame Ívane, ki delujeta kot odmev velike izgube. Ta ni izpeljan kot šok ali žanrski zasuk, temveč kot preprost, notranje konsistenten del sveta, v katerem smrt še nima trdnih kontur. Na tej točki film najjasneje razgrne svojo logiko: ne gre za vzpostavljanje dramatičnih poudarkov, temveč za ustvarjanje prostora, kjer se težko razumljive izkušnje preoblikujejo v magično-realistične elemente, ki skupaj z otroško predstavo o resničnosti določajo ton pripovedi. V tem kontekstu je pomembno sanjsko, megličasto vzdušje filma, ki ga Ester Ivakič gradi s kombinacijo zvoka, glasbe, fotografije in scenografije. Počasni delci svetlobe, ravnice in pokrajina, ki je hkrati odprta in utesnjujoča, ustvarjajo svet, ki ni povsem realističen niti povsem fantastičen, temveč liminalen prostor, kjer čarobno in vsakdanje sobivata brez potrebe po razmejitvi. Ta senzorična plast je eden najbolj izraznih in svojevrstnih elementov filma, ki z estetiko nepretencioznosti ključno soustvarja pomen. Podobno so igralske interpretacije minimalistične, zadržane in pogosto nedramatične. Lik stare mame je nekoliko prepoenostavljen na simbol starosti in minevanja, mladi igralki (Liza Muršič v vlogi Terezke in predvsem Lana Marić v vlogi naslovne Ide) pa ohranjata izrazito opazovalno držo, ki psihološko poglobitev nadomešča z občutkom otroške prisotnosti in zavedanja. Minimalizem čustveno izraznost zmanjša, vendar se to po drugi strani ujema z estetiko pripovedi, v kateri liki tu in tam niso toliko osebnosti kot bolj funkcije vzdušja. Motiv petja in religiozna motivika delujeta podobno. V naslovu film petje povzdigne v mitsko prvino, v pripovedi pa se pojavlja v nerafinirani, domačni, otroški obliki. Ida nima posluha; njeno petje nima zdravilne moči, kot si domišlja sprva, temveč je zaradi njega le tarča posmeha. Glasba in besedila, napisani za film, delujejo zavestno odmaknjeni od klasične glasbene produkcije. Gre za dosledno avtoričino strategijo, pri kateri film ne želi zveneti »filmsko«, temveč ohraniti vtis, da bi lahko te pesmi nastale v otroški sobi, med igro, brez ambicije po estetizaciji. Devica Marija ni prikazana toliko kot sakralna figura, ampak bolj kot objekt domišljije, nekakšen vsakdanji artefakt magičnega mišljenja dveh deklic. Kontrast med tem igrivim, neinstitucionalnim odnosom do religije in represivnimi pedagoškimi prijemi šole v času pozne Jugoslavije se ne razvije v kritiko sistema, temveč v še en primer preproste strategije Ester Ivakič, v kateri svet odraslih obstaja kot okvir, ne kot tema. Tem motivom se pridruži tudi nadrealistična prisotnost psičke, to je motiv, ki ga režiserka razvija že od kratkega filma Assunta naprej. Tudi tam ima žival – pes – simbolno in skoraj arhetipsko vlogo: kot prinašalec nečesa, kar presega razum odraslih in seže v otroško doživljanje sveta, kjer se naravno, čudežno in grozljivo ves čas prepletajo. Zdi se, da to, kar bi lahko poimenovali naivizem ali estetika nepretencioznosti, stopa v ospredje kot osrednji del avtorskega izraza Ester Ivakič; ker pa je igrani celovečerni film vendarle drugačna forma od poudarjeno avtorskih kratkih eksperimentalnih filmov, je bilo upravičeno pričakovati, da bo ta okvir vsaj delno avtorsko svobodo tudi omejil. Ida, ki je pela tako grdo, da so še mrtvi vstali od mrtvih in zapeli z njo kot polnokrvni celovečerni prvenec ni film, pri katerem bi bila v ospredju izoblikovanost, temveč film z dušo, ki izraža in napoveduje eno najizrazitejših avtorskih prezenc pri nas. Recenzijo je napisala Tina Poglajen. Tekst je del kulturnega projekta kritike in refleksije umetnosti z naslovom »Med enoglasjem in raznolikostjo: slovenski film v letu 2025«, ki ga je Ministrstvo za kulturo podprlo v okviru Spodbude kulturnim ustvarjalcem za izvedbo projektov kritike in refleksije umetnosti v letu 2025.

"Porque, assim como desce a chuva e a neve dos céus, e para lá não tornam, mas regam a terra, e a fazem produzir, e brotar, e dar semente ao semeador, e pão ao que come, Assim será a Minha Palavra, que sair da Minha boca; Ela não voltará para Mim vazia, antes fará o que Me apraz, e prosperará naquilo para que a enviei." Isaías 55:10-11"E disse-lhes: Ide por todo o mundo, pregai o Evangelho a toda criatura. Quem crer e for batizado será salvo; mas quem não crer será condenado." Marcos 16:15-16

Oznamovateľom korupcie ide veľakrát o živobytie, do problematickej situácie sa môže dostať aj ich rodina a nekončiaci pocit neistoty im je veľakrát odplatou za to, že zachránili peniaze daňových poplatníkov či súkromníkov. Ich ochrana teraz visí na vlásku, pretože vláda aj parlament prišli s návrhmi, ktoré rušia Úrad na ochranu oznamovateľov a nahrádzajú ho novým - Úradom na ochranu obetí trestných činov a oznamovateľov protispoločenskej činnosti. Skrátené legislatívne konanie, ako aj navrhované zmeny vzbudzujú veľké obavy o jeho nezávislosť a takisto nikto riadne nevysvetlil, prečo treba pôvodný úrad vôbec rušiť. Ide o čurillovcov? O pokuty pre ministra vnútra? Alebo nezáujem o nahlasovanie korupcie vo všeobecnosti? Aj to sa Nikola Šuliková Bajánová pýta výkonnej riaditeľky Via Iuris Kataríny Batkovej. Zdroje zvukov: TA3 Odporúčanie Blížia sa sviatky a pre mnohých to znamená trávenie času s blízkymi. Ruku na srdce, nie pre každého sú to príjemne pokojné a radostne strávené chvíle. Práve preto prichádza ten správny čas pripomenúť si starší text od Jancee Dunnovej pre NY Times, v ktorom so svojimi respondentmi, medzi nimi aj bývalým šéfom jednotky krízového vyjednávania v FBI, rozoberá, ako rozptýliť dusnú atmosféru počas rodinných stretnutí. Základné rady sa dajú zhrnúť takto: nepovzbudzujte, parafrázujte, označujte pocity, zrkadlite, pýtajte sa otvorené otázky, komunikujte cez „ja“, nechajte vyznieť ticho. – Všetky podcasty denníka SME nájdete na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠sme.sk/podcasty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – Odoberajte aj audio verziu denného newslettra⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ SME.sk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ s najdôležitejšími správami na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠sme.sk/brifing⁠⁠⁠See omnystudio.com/listener for privacy information.

Špeciálna epizóda Week 13 je tu – tentokrát spájame klasické NFL štúdio s Fantasy Start/Sit!Prechádzame všetky zápasy Thanksgiving týždňa, hodnotíme dôležité matchupy a po každom preview pridávame aj fantasy pohľad: koho postaviť, koho radšej posadiť a na čo si dať pozor pri rozhodovaní.Rozoberáme aj návrat Joea Burrowa, formu Eagles po zakopnutí, súboj Vikings s undrafted QB nováčikom či otázku, či Giants pustia ďalší zápas.Na záver odpovedáme na otázky divákov.Ideálny mix NFL analýzy a fantasy rád pred kľúčovým týždňom sezóny.0:00:28 Úvod + Súťaž0:14:00 Packers @Lions 0:29:55 Chiefs @ Cowboys0:45:10 Bengals vs Ravens0:56:25 Bears @ Eagles1:06:46 Komerční intermezzo aneb poděkování partnerůmprojektu NFL.cz1:11:40 49ers @ Browns1:20:17 Jaguars @ Titans1:25:50 Texans @ Colts1:36:18 Saints @ Dolphins1:45:30 Falcons @ Jets1:48:28 Cardinals @ Buccaneers1:56:30 Rams @ Panthers2:01:40 Vikings @ Seahawks2:09:00 Bills @ Steelers2:13:55 Raiders @ Chargers2:21:22 Komerční intermezzo aneb poděkování partnerůmprojektu NFL.cz2:24:30 Broncos @ Commanders2:30:20 Giants @ Patriots2:39:05 Sázkařské okienko s Fortunou2:44:00 Odpovede na otázky z NFL Fantasy

O evangelismo começa onde estamos. Proclamar o evangelho não é dever somente dos missionários de tempo integral.É mais comum pensarmos que missionários são apenas aqueles que estão em terras distantes, do que em relação a nós, que devemos ser em todo o local que estivermos. O IDE significa sair da zona de conforto. A ordem do IDE é para todos os cristãos. #conscienciacrista #cc2026 #EUSOU #vidacrista #ide #evangelismo #biblia #missionarios

Panelists: Paul Hagstrom (hosting), Quinn Dunki, Jack Nutting, and Blake Patterson Topic: 1986 IDE, IMAP, IIGS, and even some other things that do not begin with “I” were introduced in 1986. Topic/Feedback links: Retro Computing News: Vintage Computer(-related) commercials: Retro Computing Gift Idea: Auction Picks: Closing notes: Other ways to experience this episode: Feedback/Discussion: Intro … Continue reading RCR Episode 286: Somehow all Myst →

V zdravotníctve sa šetrí na všetkých frontoch. Do systému nové lieky prakticky nevstupujú a na výnimku sa k ním už nedostaneme. Budeme cestovať do zahraničia a platiť si liečbu z vlastného vrecka? Pýta sa predsedníčka Slovenskej aliancie zriedkavých chorôb Tatiana Foltánová. Záleží štátu na našich životoch? Ak áno, prečo to necítia naši najzraniteľnejší?Sú tu, všade medzi nami. Naše mamy, otcovia, sestry, bratia či dokonca i naše vlastné deti. Sú ich státisíce a bojujú o svoj život, o vlastné prežitie či aspoň o akú takú kvalitu ich života. Ľudia zo zriedkavými ochoreniami, či tí, ktorí potrebujú moderné lieky alebo inovatívnu liečbu. A sú ich státisíce.Namiesto toho aby ich problémy riešil náš zdravotnícky systém, do ktorého už i tak nalievame zhruba 10 miliárd - a v ktorom je priestor i na také niečo, ako sú zisky Zdravotných poisťovní, ich dnes ale čoraz častejšie stretávame na charitatívnych internetových zbierkach, kde doslova žobrú o možnosť holého prežitia. I to je Slovensko v roku 2025.Ide totiž o lieky, ktoré môžu zachrániť život, alebo výrazne zlepšiť zdravotný stav – no pacienti sa k nim neraz nedostanú. Minister zdravotníctva totiž tieto lieky prakticky stopol a odôvodňuje to najmä argumentom finančnej neudržateľnosti či netransparentnosti systému. V tejto rovnici tak ide ako o naše životy a zdravie, ako aj o ozaj veľké peniaze, či proste snahu skonsolidovať verejné výdavky.Po prakticky pol roku intenzívnych rokovaní o tejto téme však strešné propracientské a pomáhajúce organizácie dávajú od vyjednávania s ministerstvom zdravotníctva ruky preč a rokovania pozastavujú. To, čo táto vláda pripravuje, rozhodne nie je to, čo by pacientom pomohlo. Pacientom sa pohorší, nielen tým so zriedkavými ochoreniami, ale nám všetkým, varuje T. Foltánová. Už lekári samotní odporúčajú takýmto pacientom aby si zakladali crowdfundingové darovacie výzvy a to i pre pacientov v ozaj vážnych zdravotných peripetiách so zriedkavým či onkologickým ochorením, dodáva Stískalová. Aký bol dôvod rokovania stopnúť a skutočne tejto údajne sociálnodemokratickej a národnej vláde záleží na našich životoch a zdraví? Aká je cena nášho života na dnešnom Slovensku? Ako nastaviť systém liečby zriedkavých ochorení, prístupu k moderným inovatívnym liekom a dá sa na tom ušetriť tak, aby sme zbytočne neumierali? No a prečo sa vlastne musíme na takúto liečbu zbierať na Doniu, keď si i tak platíme zdravotné odvody a do zdravotníctva rok čo rok tečú nemalé miliardy? Témy pre Simonu Stískalovú z Platformy pomáhajúcich organizácií a Tatianu Foltánovú, predsedníčku Slovenskej aliancie zriedkavých chorôb. Počúvate Ráno Nahlas, pekný deň a pokoj v duši praje Braňo Dobšinský.

Hans und Schepp sprechen darüber, wie weit „Vibe-Coding“ im Vergleich zu AI-Assist in der IDE wirklich trägt. Hans bringt sein Experiment mit, dokumentiert im Blogpost, und wir ordnen ein, wo AI uns T…

Współpraca międzynarodowa i mądre wsparcie rozwojowe są kluczem do trwałej zmiany. Ideę tę ilustruje projekt Fundacji Ekonomicznej Polska - Afryka Wschodnia, która od lat angażuje się w rozwój przedsiębiorczości i edukacji rolniczej w Tanzanii, u podnóża Kilimandżaro. Założyciele Fundacji, Małgorzata i Robert Zduńczyk, wykorzystali doświadczenia polskiej transformacji gospodarczej do wsparcia lokalnej spółdzielni rolników mleczarzy.Projekt, finansowany m.in. z programu Polska pomoc MSZ, polega na modernizacji mleczarni i rozwoju rolniczej szkoły zawodowej. Przykładem takich działań są nowe, w tym miejscu, metody żywienia krów i edukacja praktyczna. Pomimo różnic kulturowych, cierpliwe budowanie zaufania i inwestowanie w ludzi przyniosło  efekty, a skup mleka wzrósł kilkakrotnie.Inicjatywa stworzyła stabilne miejsca pracy dla młodych Tanzańczyków, przez co przeciwdziała migracji i wspiera rozwój lokalnego rolnictwa. Długofalowy sukces polega na przekazywaniu odpowiedzialności lokalnym menedżerom, co jest dowodem na to, że pomoc oparta na partnerstwie i budowaniu kompetencji realnie zmienia świat.Polska pomoc to program polskiej współpracy rozwojowej Ministerstwa Spraw Zagranicznych. Realizowany jest w krajach, które mierzą się z kryzysami i wyzwaniami rozwojowymi. To działania, które mają sens i historię, które pokazują, jak pomoc zmienia życie ludzi.

Mark “Murch” Erhardt, Gustavo Flores Echaiz, and Mike Schmidt are joined by Antoine Poinsot and ZmnSCPxj to discuss Newsletter #381.News● Modeling stale rates by propagation delay and mining centralization (1:03) ● Private key handover for collaborative closure (30:55) Changes to services and client software● Arkade launches (52:32) ● Mempool monitoring mobile application (55:25) ● Web-based policy and miniscript IDE (56:25) ● Phoenix Wallet adds taproot channels (57:45) ● Nunchuk 2.0 launches (59:19) ● LN gossip traffic analysis tool announced (1:01:49) Notable code and documentation changes● Bitcoin Core #33745 (1:04:23) ● Core Lightning #8537 (1:09:28) ● Core Lightning #8608 (1:11:26) ● Core Lightning #8646 (1:13:34) ● Core Lightning #8569 (1:17:44) ● Core Lightning #8558 (1:22:46) ● LDK #4126 (1:24:11) ● LDK #4208 (1:26:37) ● LND #9432 (1:27:58) ● BOLTs #1284 (1:31:38) ● BOLTs #1044 (1:33:33)

Topics covered in this episode: PEP 814 – Add frozendict built-in type From Material for MkDocs to Zensical Tach Some Python Speedups in 3.15 and 3.16 Extras Joke About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Michael #0: Black Friday is on at Talk Python What's on offer: An AI course mini bundle (22% off) 20% off our entire library via the Everything Bundle (what's that? ;) ) The new Talk Python in Production book (25% off) Brian: This is peer pressure in action 20% off The Complete pytest Course bundle (use code BLACKFRIDAY) through November or use save50 for 50% off, your choice. Python Testing with pytest, 2nd edition, eBook (50% off with code save50) also through November I would have picked 20%, but it's a PragProg wide thing Michael #1: PEP 814 – Add frozendict built-in type by Victor Stinner & Donghee Na A new public immutable type frozendict is added to the builtins module. We expect frozendict to be safe by design, as it prevents any unintended modifications. This addition benefits not only CPython's standard library, but also third-party maintainers who can take advantage of a reliable, immutable dictionary type. To add to existing frozen types in Python. Brian #2: From Material for MkDocs to Zensical Suggested by John Hagen A lot of people, me included, use Material for MkDocs as our MkDocs theme for both personal and professional projects, and in-house docs. This plugin for MkDocs is now in maintenance mode The development team is switching to working on Zensical, a static site generator to overcome some technical limitations with MkDocs. There's a series of posts about the transition and reasoning Transforming Material for MkDocs Zensical – A modern static site generator built by the creators of Material for MkDocs Material for MkDocs Insiders – Now free for everyone Goodbye, GitHub Discussions Material for MkDocs still around, but in maintenance mode all insider features now available to everyone Zensical is / will be compatible with Material for Mkdocs, can natively read mkdocs.yml, to assist with the transition Open Source, MIT license funded by an offering for professional users: Zensical Spark Michael #3: Tach Keep the streak: pip deps with uv + tach From Gerben Decker We needed some more control over linting our dependency structure, both internal and external. We use tach (which you covered before IIRC), but also some home built linting rules for our specific structure. These are extremely easy to build using an underused feature of ruff: "uv run ruff analyze graph --python python_exe_path .". Example from an app I'm working on (shhhhh not yet announced!) Brian #4: Some Python Speedups in 3.15 and 3.16 A Plan for 5-10%* Faster Free-Threaded JIT by Python 3.16 5% faster by 3.15 and 10% faster by 3.16 Decompression is up to 30% faster in CPython 3.15 Extras Brian: LeanTDD book issue tracker Michael: No. 4 for dependencies: Inverted dep trees from Bob Belderbos Joke: git pull inception

„Šansonové zpívání je taková zprofanovaná věc, že přijde nějaký zpěvák a začne hrát prožitek a hned se tomu říká šanson,“ říká zpěvák Ondřej Ruml. „Ideální je, když si text, který zpíváš, připodobníš k něčemu, co jsi skutečně zažila nebo co jsi viděla. A v ten moment nemusíš nic hrát,“ vysvětluje. Jak bude znít jeho nová deska? Inspirovali ho při tvorbě Pink Floyd? A kdy začal veřit svému hlasu? Poslechněte si rozhovor.Všechny díly podcastu Host Lucie Výborné můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Youtube Channel: https://www.youtube.com/@GenerativeAIMeetup Mark's Travel Vlog: https://www.youtube.com/@kumajourney11 Mark's Personal Youtube Channel: https://www.youtube.com/@markkuczmarski896 Attend a live event: https://genaimeetup.com/ Shashank Linked In: https://www.linkedin.com/in/shashu10/    In this episode of the Generative AI Meetup Podcast, Mark (in Ohio) and Shashank (in India) finally sit down after a month of travel to unpack a very eventful stretch in AI. They dive into Google's new Gemini 3 Pro, its standout scores on Humanity's Last Exam and ARC-AGI, and why these reasoning benchmarks matter more than yet another near-perfect standardized test score. Mark also makes a public feature request to DeepMind: please increase Gemini's max output tokens. From there they get hands-on with the developer experience: Google's new Anti-Gravity coding IDE (and how it compares to Cursor) Using GPT-5.1 Codex High in Cursor's autonomous “plan mode” Why long context and long output windows are critical for deep research and book-length projects The conversation then shifts to the bigger picture: LLMs as therapists, sycophancy, safety, and the danger of AI always agreeing with you Mark's rant on robotics, humanoid robots, and a coming age of extreme abundance where robots handle most physical and intellectual work Why learning to code may become the mental equivalent of going to the gym—a “brain gym” in a world where AI can do most practical tasks They also cover the latest AI industry drama and milestones: Yann LeCun leaving Meta, what that might signal about Big Tech AI labs, and how godfathers like Hinton, LeCun, and Bengio see the road to AGI DeepMind's new game-playing agent and why world models in 3D environments matter for real-world robotics Genspark hitting unicorn status and what it means for “ChatGPT wrapper” startups Co-inventing a new term on air: a “narwhal” = a trillion-dollar private company If you're curious about where frontier models, coding agents, robotics, and AGI trajectories all intersect—plus some philosophical musing on jobs, meaning, and abundance—this episode is for you.

This episode covers: • Nano CBD Pain Relief Without Cognitive Side Effects A new nano-micelle formulation of CBD called CBD-IN delivers fast, non-addictive pain relief in mice without memory issues, motor impairment or the usual cannabinoid “fog.” Because it crosses the blood brain barrier and directly targets hyperactive pain circuits, it sidesteps many opioid-type drawbacks. Dave explains why precision-designed cannabinoids could reshape chronic pain treatment and longevity support. Source: https://www.sciencedaily.com/releases/2025/11/251117095652.htm • Moderate Calorie Restriction Slows Biological Aging A long-term trial from the National Institute on Aging found that cutting calories by about 12% over two years slowed the pace of aging — measured by methylation clocks and metabolic markers — in lean and mildly overweight adults alike. Dave breaks down why small, manageable dietary tweaks can deliver big longevity gains, without crash dieting or extreme fasting. Source: https://www.nia.nih.gov/news/cutting-calories-may-slow-pace-aging-healthy-adults • FDA Approves AI-Guided Robotic Surgery Trials for Alzheimer's The U.S. Food and Drug Administration (FDA) has granted IDE approval for the first robotic microsurgical study targeting early stage Alzheimer's disease using AI and deep imaging. The trial uses adaptive robotics to target deep brain lymphatic pathways, potentially clearing amyloid/tau deposits with surgical precision. Dave explains why this signals a new era in neurodegeneration – moving from drug-only to machine-assisted brain repair. Source: https://www.mmimicro.com/ide-approval-for-first-robotic-microsurgery-alzheimers-study/ • Antibiotic Reprograms Gut Bacteria to Produce Anti-Aging Molecules Researchers demonstrated that the veterinary antibiotic cephaloridine can reprogram gut microbes to secrete colanic acid — a molecule linked to better mitochondrial health, reduced gut permeability and improved cholesterol/insulin balance in mice. Dave explores how this could evolve into a pipeline of engineered probiotics that act as internal “longevity factories.” Source: https://newatlas.com/aging/antibiotic-longevity-microbiome/ (link remains unchanged) • Klotho: The Longevity Protein Nears Clinical Reality The longevity protein Klotho, known for clearing toxic by-products, calming inflammation and protecting brain/organ networks, is now advancing toward human trials via injectables, oral formats and gene therapy. Dave explains why Klotho is shaping up as a foundational target for next-gen age-reversal strategies and stacking protocols. Source: https://investingnews.com/longevity-focused-health-fueling-u-s-anti-aging-products-market-projected-to-reach-27-billion-by-2033/ (link remains unchanged) All source links provided for easy reference to the original reporting and research above. This episode is essential listening for fans of biohacking, human performance, functional medicine and longevity who want practical tools from Host ­Dave Asprey and the latest breakthroughs shaping the future of health. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade gives you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence and conscious living. New episodes are released every Tuesday, Thursday, Friday (audio only) and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: nano CBD, CBD-IN, pain relief research, non opioid pain therapies, chronic pain and aging, caloric restriction aging, methylation clocks, metabolic resilience, AI robotics, Alzheimer's microsurgery, neurotech advancement, microbiome engineering, colanic acid, longevity probiotics, mitochondrial support, Klotho protein, anti aging gene therapy, cellular rejuvenation, longevity news, biohacking updates Thank you to our sponsors! LYMA | Go to https://lyma.sjv.io/gOQ545 and use code DAVE10 for 10% off the LYMA Laser. Vibrant Blue Oils | Grab a full-size bottle for over 50% off at https://vibrantblueoils.com/dave. Resources: • Subscribe to my weekly newsletter: https://substack.daveasprey.com/welcome • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 — Intro 0:19 — Story 1: Nano CBD for Pain Relief 1:53 — Story 2: Caloric Restriction and Aging 3:20 — Story 3: AI Robotic Surgery for Alzheimer's 4:50 — Story 4: Microbiome Reprogramming 6:05 — Substack Announcement 7:04 — Story 5: Klotho Longevity Protein 8:39 — Weekly Homework 9:31 — Outro See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Bývalý podpredseda vlády pre plán obnovy Peter Kmec v otvorenom rozhovore v relácii Ide o pravdu vysvetlil dôvody svojej demisie, spornej inovačnej výzvy aj napätia medzi koaličnými partnermi. Kritizoval aj premiéra Roberta Fica za rozdielny prístup k partnerom koalície: "Cítiť tam dvojaký meter…".

Gemini 3.0 just dropped, grabbing the "Best LLM" crown and completing Google's epic AI comeback! We break down the need-to-knows, including:Google's ambitious Antigravity agent-first IDE.Why G3 broke every benchmark except coding.The rise of AI-generated music (1 in 3 streams!).The truth about AI's water usage.The winners and losers after Gemini 3 Day.Plus: A check-in on the AI bubble after Oracle's Open AI deal crash.

Hypotéza 38: Ako Božia milosť často učí tých, ktorí sa o seba starajú a zverujú sa do jeho prozreteľnosti, ktorá ich vedie prostredníctvom jednoduchých ľudí a cudzincov; pokorní sa neodmietajú učiť od každého, koho môžu stretnúť.   Filokalia Live - pravidelné online formačné stretnutia. Zámerom je spoznávanie a osvojovanie umenia duchovného života štúdiom učenia svätých otcov. Štvrtkové stretnutia sú venované uvažovaniu nad dielom Evergetinos. Ide o rozsiahlu zbierku výrokov a krátkych príbehov zo života púštnych otcov, ktorá bola zostavená mníchom Pavlom v 11. storočí. Každá kapitola dáva dôkladné vysvetlenie predstavenej témy a postupne čitateľa sprevádza od položenia základných kameňov duchovného život až po jeho výšiny. Stretnutia sa konajú každý pondelok a štvrtok o 20.00 hod. V prípade záujmu sa môžete zaregistrovať a e-mailom Vám bude zaslaný link pre vstup na stretnutie.  

You ever see a new AI model drop and be like.... it's so good OMG how do I use it?

In this episode of the Interventional Glaucoma podcast, Prof. Gus Gazzard speaks with Dr. Neeru Vallabh and Mr. Dirk Mühlhoff about how excimer laser technology is transforming glaucoma treatment. They discuss Excimer Laser Trabeculostomy (ELT), which uses ultraviolet light to create precise, non-thermal microchannels in the trabecular meshwork, improving natural fluid outflow. The conversation highlights how this laser, long used in refractive surgery, is now offering a safe, minimally invasive option for glaucoma patients.   The ELIOS system (Bausch & Lomb) is manufactured by MLase GmbH, located at 82110 Germering, Industriestr. 17, Germany and by WEINERT Fiber Optics GmbH, Mittlere-Motsch-Strasse 26, 96515 Sonneberg, Germany.  ELIOS is CE marked for use in adult patients with glaucoma and is currently under investigational use in the US as part of an ongoing IDE study (FDA). The ExTra II (laser class 4) has the brand name ELIOS. The ExTra II is equivalent to ExTra and AIDA devices.  Find out more about ELIOS : http://bit.ly/4lWBJZ1

Gemini 3 is officially here. ✨ ✨ ✨For about 8 months, Gemini 2.5 Pro has mostly maintained its standing as the top LLM in the world yet Google just unleashed its successor in Gemini 3.0. So, what's new in Gemini 3? And whether you're a developer or casual user, what does Google's new model unlock? Join us as we chat with Google's Logan Kilpatrick's for all the answers. Gemini 3: What's new and what it unlocks for your business with -- An Everyday AI Chat with Google DeepMind's Logan Kilpatrick and Jordan WilsonNewsletter: Sign up for our free daily newsletterMore on this Episode: Episode PageJoin the discussion: Thoughts on this? Join the convo and connect with other AI leaders on LinkedIn.Upcoming Episodes: Check out the upcoming Everyday AI Livestream lineupWebsite: YourEverydayAI.comEmail The Show: info@youreverydayai.comConnect with Jordan on LinkedInTopics Covered in This Episode:Gemini 3 Release Overview & FeaturesState-of-the-Art AI Benchmarks ExceededGemini 3 in Google Ecosystem ProductsGemini 3 Vibe Coding Capabilities DemoNon-Developer Use Cases for Gemini 3Multimodal Understanding and VisualizationsAgentic AI Tools: Gemini Agent & Anti GravityBusiness Growth with Gemini 3 AI IntegrationTimestamps:00:00 Gemini 3: State-of-the-Art AI05:59 "Gemini 3: Build Ambitiously"08:16 "AI Studio: Bringing Ideas Alive"12:44 Gemini App Agents & Anti-Gravity14:57 "Enhancing AI as a Thought Partner"17:01 AI Studio: Build Apps FasterKeywords:Gemini 3, Gemini 3 Pro, Google AI, AI Studio, Vibe Coding, multimodal model, agentic coding, tool calling, anti gravity, generative interfaces, Gemini app, APIs, AI capabilities, interactive experience, visual dashboard, bespoke visualization, state-of-the-art model, developer platform, agentic developer tools, benchmark results, code editor, IDE integration, product experiences, infrastructure teams, triage inbox, personal assistant, proactive agents, 2.5 Pro, model capability, product feedback, code generation, gallery applets, build mode, ambition in AI, software engineering, feature enhancement, thought partner, AI-powered building, on demand experience, interactive visualizations, coding advancements, user engagement, real-time rollout.Send Everyday AI and Jordan a text message. (We can't reply back unless you leave contact info) Head to AI.studio/build to create your first app.  Head to AI.studio/build to create your first app. 

Topics covered in this episode: Possibility of a new website for Django aiosqlitepool deptry browsr Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Brian #1: Possibility of a new website for Django Current Django site: djangoproject.com Adam Hill's in progress redesign idea: django-homepage.adamghill.com Commentary in the Want to work on a homepage site redesign? discussion Michael #2: aiosqlitepool

Do dôchodku vstupuje s dlhom 30 % Američanov a približne pätina Európanov. Ako je to na Slovensku? Aké sú možnosti, ale najmä riziká zadlžovania starších ľudí? V podcaste sa dozviete: Prečo sa v súčasnosti zadlžujú aj ľudia nad 50 rokov v súčasnosti?  Aké sú možnosti a pravidlá natiahnuť si úver až do dôchodkového veku a na druhej strane dostať úver ako dôchodca? Ktoré typy úverov (hypotéky, spotrebné úvery, kreditné karty) predstavujú najväčšie riziko pre finančnú stabilitu tejto vekovej skupiny a prečo? Sú starší ľudia finančne disciplinovanejší?  V akej miere môže klient 10 rokov pred odchodom do dôchodku realisticky odhadnúť svoju budúcu finančnú situáciu a schopnosť splácať? Čelí táto veková skupina reálne hrozbe tzv. "dvojitého šoku" – teda výrazného poklesu životnej úrovne pri prechode na dôchodok, ku ktorému sa pridáva nevyhnutnosť splácať záväzky? Ako sa na úvery v dôchodkovom veku pozerať z pohľadu zhoršovania zdravotného stavu a vyššej potreby peňazí na jeho riešenie? V relácii Ide o peniaze odpovedá Pavel Škriniar z katedry ekonómie Národohospodárskej fakulty Ekonomickej univerzite v Bratislave.

Herečka Natália Germáni patrí k najobsadzovanejším slovenským herečkám svojej generácie, jej život sa však už niekoľko rokov odohráva na dvoch kontinentoch. Medzi Slovenskom a Amerikou pendluje nielen kvôli rodine, ale aj novým pracovným výzvam, ktoré ju formujú ako umelkyňu aj ako človeka.  Do nášho štúdia priletela priamo z New Yorku, aby predstavila svoj nový film Neporaziteľní a otvorene prehovorila nielen o profesionálnom, ale aj súkromnom živote a jeho smerovaní. Práve rola v novej českej dráme Neporaziteľní ju zasiahla hlbšie, ako čakala. „Po natáčaní som si veľa naplakala,“ priznáva herečka.  Tento rok - krátko pred nástupom Donalda Trumpa do úradu - získala v USA pracovné víza. Podarilo sa jej hrať v predstavení na Broadway a natočiť jeden film. Život v Amerike však nie je len o úspechu. Je to aj o neustálom boji o rolu a každodennom dokazovaní svojich kvalít na jednom z najdrsnejších trhov sveta. „Amerika ma naučila povedať si o svoju cenu a nehanbiť sa pochváliť,“ vysvetľuje. Za rozhodnutím skúsiť šťastie za oceánom stál predovšetkým jej manžel. Natália s úsmevom priznáva, že bez jeho impulzu by pravdepodobne nikdy neopustila svoju komfortnú zónu. V rozhovore sme však otvorili aj ďalšie témy. Ako zvláda výchovu dvoch dcér na dvoch kontinentoch? Aké je to natáčať film v ôsmom mesiaci tehotenstva? Ako vníma politickú situáciu v Amerike a či sa jej dotýka ako umelkyne? A prečo by svoje dcéry bez váhania podporila v umeleckej kariére, aj keby mali byť manikérky? Dozviete sa ešte omnoho viac v novej epizóde Ide o nás - Rozhovory so Zdenom Gáfrikom.

Santo Espírito (parte 12) - Gabriel Manzoni by IDE

Kaya and Faisal break down the rise of a Muslim founder whose AI company is now valued at $3B—from coding in a Jordanian internet café and getting rejected by YC four times… to building a browser-based IDE in 2016, then pivoting into agentic AI that codes, debugs, and deploys while you sleep. We pull out the real lessons: grit over hype, "die on the path," and why building within halal limits brings barakah (with cautionary stories about riba). We also spotlight MENSPIRE, a global barbershop chain built on Muslim values (no music, no gossip, family-safe) that still scaled—proof you can build infrastructure for the community without compromising. Plus: dopamine from doing (not doom-scrolling), showing up daily, and being agile like water when markets shift.

Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author, Professor Sundar Jagannath, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Tisch Cancer Institute. He also serves as Network Director for the Center of Excellence for Multiple Myeloma, and he is an internationally recognized expert in the field of multiple myeloma. Today, we will be discussing the article titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." Thank you for speaking with us, Professor Jagannath. Dr. Sundar Jagannath: Thank you for having me, Dr. Davide Soldato. It is a pleasure to be here. JCO is a highly recognized journal among the oncologists, so I am very happy and privileged to be here today. Dr. Davide Soldato: Thank you so much for being with us. So, I wanted to start a little bit with the rationale of the study and the population that was included in the study. So, the trial that we are discussing, CARTITUDE-1, was already published before, and we observed very good results with a single infusion of cilta-cel. So we had previously reported a median progression-free survival of 30 months, and median overall survival was not reached. So, I just wanted to ask you if you could guide us a little bit into the population that was included in the study and also explain a little bit to our listeners what is the drug that we are discussing, cilta-cel. Dr. Sundar Jagannath: It is a CAR T-cell. This is a patient's own lymphocytes, which goes through apheresis and is sent to the company, where they modify it and introduce the B cell receptor. In this case, you know, there is a heavy chain gene receptor for the BCMA, and in cilta-cel, there are actually two receptor sites on each molecule, or there are two binding domains on each receptor molecule. So, it is considered to be quite efficacious. As you reported, the earlier results that the patients who participated, 97% of the patient responded. Now, you asked about the patients who participated in the clinical trial. This clinical trial was conducted between July of 2018 and October of 2019. At that time, this was a phase 1b/phase 2 trial, and the whole idea was to take patients who had relapsed all the available treatment regimen so that these patients were considered to have, in the unmet medical need situation. So, what does that entail? That means the patient should have been exposed to a proteasome inhibitor, to an immunomodulatory molecule, and to an anti-CD38 monoclonal antibody and should have received at least three or more prior lines of therapy and should be actually progressing on their last line of therapy. So with that requirement, if you look at it, the median number of prior therapy on the patients who participated was actually six. So patients were heavily pretreated. They had exhausted all available treatment options. So, they can participate in this clinical trial. And if not, there have been real-world evidence, such as LocoMMotion, which had reported what is the outcome for such a patient if they were treated outside of this clinical trial, if they were treated with the then available regimen. Their median progression free survival would have been only 3 months, and most patients would have lost their life within a year. So, this was truly an unmet medical need with patients in a very difficult clinical situation. Let's put it that way. So, those were the patients who participated in this particular trial. Dr. Davide Soldato: Thank you very much. And as we mentioned before, the results that were obtained in this clinical trial were really very interesting. And now, in this issue of the Journal of Clinical Oncology, you are reporting data with a longer follow up. So we are actually at more than 5 years of follow up for the patients included in this trial. So, I just wanted a little bit of insight into why you decided to report these long-term outcomes and what type of information do you think you could provide with this study to the medical community? Dr. Sundar Jagannath: This is very important because this was a clinical trial that was done in patients who were, as I said, in unmet medical need. Most of the patients had prior stem cell transplantation, had gone through a proteasome inhibitor. Many of them have had both Velcade and carfilzomib treatment. Most of them had been exposed to lenalidomide and pomalidomide. And as required, all of the patients had to have had prior exposure to anti-CD38 monoclonal antibody or daratumumab. So, the patients were heavily pretreated. Typically, TIL CAR T-cells came into the field at this particular moment, until then, we were developing small molecules, and they usually would have a PFS of 3 months and median life expectancy of a year, the overall response rate of 30%, and that is how, if you look back, that is how carfilzomib was approved, that is how pomalidomide was approved. So, the drugs which were approved, including daratumumab, you know, the response rate was in the same ballpark. So you would see that most agents, single agents, would have had a response rate in the neighborhood of 30%, the progression-free survival would have been between 3 to 5 months or 6 months at the most, and the life expectancy was short. And here comes a drug, and when I was following the patients at Mount Sinai, I found that there were a subset of patients, they got one-time treatment and they were in complete remission, no trace of cancer with annual evaluation with PET CT and bone marrow evaluation for MRD. So, I said this is remarkable, and this needs to be reported. And I went to the Janssen and company, and they agreed to review the entire experience. This is remarkable that 32 of the 97 patients, or one third of the patients, were alive and progression-free. This is unheard of for any clinical trial until now, that the patient will be progression-free, one third of the patients on a clinical trial will be progression-free, in the late stage of their disease. So that is the most important impact. And that is why this 5-year follow-up results were presented. Dr. Davide Soldato: Thank you very much. That was very clear. And as you said, we are speaking about a population that was heavily pretreated, that had exhausted all type of treatment options outside of a clinical trial. And as you said, one third of the patients was alive and progression-free after 5 years from being included and infused inside of the study. So, considering this population that, as we said, had received all treatment options, I was wondering if you observed any kind of differences in terms of disease characteristics when looking at these patients that had exceptional response, so, alive and progression-free at 5 years, and the patients that sadly had developed a progression after the infusion in the study. Dr. Sundar Jagannath: This is very important because we wanted to see who are the patients who are having this exceptional outcome. And we looked at all the 97 patients. If we look at all the patients, we saw that there were initially, out of the 97, 17 patients died earlier in the disease course due to treatment related complications, etc. But there were about 46 patients who had progression of disease and 32 patients, or one third, were alive without progression of disease. Then we looked at the 46 patients who had progression of disease. Of them, we found that 30 had disease progression and its complication, and there were actually 13 patients who were still alive even after progression of disease. So we decided to compare these 46 patients who had progression of disease versus 32 patients who had no progression of disease to see what is the difference. To our surprise, the age was similar, male, female distribution was similar. High-risk cytogenetics, which we would have thought, you know, that is why we say high-risk disease, the term, high-risk cytogenetics was equally distributed. That was really a surprise. Number of lines of prior therapy, number of exposure to drugs, all of that was the same. So that was also interesting. But a theme did emerge. Patients, in general, tend to have lower burden of disease who had the exceptional outcome. But there is one which we considered as bad, the extramedullary disease. Multiple myeloma being a blood cancer, it is usually in the bone marrow. When it starts growing outside of the bone marrow, the extramedullary disease, usually it portends poor prognosis. But we were surprised that actually there were an equal number of extramedullary disease patients even in the long-term survivor as those who had progressed of disease. So the most important takeaway was patients who had lower burden of disease, they had less number of myeloma cells in their bone marrow, percentage wise, and the soluble BCMA level was lower. Soluble BCMA is an indirect measure of the amount of plasma cells in the patient's body. It is like a tumor burden. So they were low. So, this was an important finding because it has future ramification, as you can understand. If this treatment is made available earlier in the disease course of the patients, where we are able to control the disease better, then more patients are likely to have such wonderful outcomes as one third of the patient experience in the late stage of the disease. Dr. Davide Soldato: So, you already mentioned soluble BCMA as a marker of potentially better prognosis as being correlated to a lower volume of disease. I was wondering if you could give us some more information about the biomarkers that you evaluated in the study. For example, you evaluated a little bit the CAR T expansion kinetics and also some others that I think could be interesting and could point to some population that experienced such important benefit. Dr. Sundar Jagannath: That is a very important point because CAR T-cell, it is a live cell and its efficacy depends upon how well the CAR T-cell is going to function. And then, you know, the patient undergoes apheresis. This is a patient's own lymphocyte. So first and foremost is who would generate good CAR T-cell. Those who have plenty of lymphocytes at the time they are coming for apheresis. This is likely to happen earlier in the course of the disease than in patients who have gone through numerous lines of therapy and exhausted. So, in this particular trial, of course this was in late stage of the disease, and so we were able to show patients who had lower number of T cell in circulation, and the way to measure is if they had more neutrophils and less lymphocytes. So that is what is called as a higher T cell over neutrophil, they did better. If they have more neutrophil than T cells, then they did not do well. So, procurement. The second one is also whether the T cells are more naive, you know, not exhausted T cells. So more naive T cells, if you are able to procure from the patient, they did very well. Now, after the CAR T-cell manufacture, then the expansion, when you put it back into the patient, if the T cells expand very well, so that the effector, that is the CAR T-cells to the tumor ratio is good, so there are more effector cells, the CAR T was able to expand and the amount of tumor was less, then the efficacy was very, very good. As I said, the patients in this group, those who had a lower burden of disease, they did better, and that is because of the CAR T-cell expansion, so the effector to the target ratio was favorable. So that is another important. And then there are also the type of CAR T-cells, having CD4 T cells with central memory phenotype at the peak expansion also makes a difference. So all of that matters. But this is important because the efficacy of the CAR T-cell, it is persistent, long persistent and keeping the cancer down. Its ability to get rid of the cancer completely at the first go around because usually we are not able to detect the CAR T-cells beyond 6 months in the majority of patients and very rarely after a year or two. So it is very uncommon to find the CAR T-cells in circulation or even in the regular bone marrow evaluation. So, efficacy, the expansion, having naive T cells, having good effector to target ratio and more central memory kind of T cell, because if it is all effector T cell, they will get quickly utilized and get exhausted, whereas the central memory cells can expand more and give more effective CAR T-cells. Dr. Davide Soldato: Thank you very much. I was wondering if you could guide us a little bit into what is your opinion regarding the positioning of CAR T-cells given all of these logistics that is necessary compared, for example, with bispecific antibodies against BCMA, which have the same target, but they do not have all of these logistics before being administered to the patient. Dr. Sundar Jagannath: That is a very important question, how to sequence these treatments now that we have two BCMA-directed CAR T-cells available. We have three BCMA-directed bispecific and one GPRC5D-directed bispecific antibodies are available. And so the question comes in for at least the currently approved CAR T-cell therapy, there is an obligatory time. You have to go through apheresis and you have to ship to the company, and there is a manufacturing time, roughly about 2 months before they can receive it. During that time, you want to make sure the patient's disease is under control. So that is a given. There are several ways to look at it when we evaluate the patient and talk to the patient. One good thing is now the two CAR T-cells which are approved, one is cilta-cel we talked about, and the other one is ide-cel. Ide-cel is approved in earlier line of therapy, two or more prior lines of therapy, and cilta-cel is approved in patients who have failed one line of therapy and who are lenalidomide refractory. So, the treatment of CAR T-cell is available earlier. And as I said, when you administer CAR T-cell earlier, you are able to keep the disease burden down, and it is a one and done deal. There is a better quality of life for the patient, and you are able to produce long, durable remission and potentially a cure. Now coming to the bispecific, they are currently available in later lines of therapy. So if you look at it from a patient's perspective, you can use the CAR T-cell earlier and then go through the bispecific therapy. But if the patient comes with relapsed refractory myeloma and has not used the CAR T-cell therapy and has not used the bispecific therapy, then the physicians have to decide which one they want to use. If somebody's disease is rapidly progressing and they need immediate tumor reduction and they have already exhausted all available therapy, then going through BCMA bispecific therapy is quite appropriate. And secondly, CAR T-cell therapy is generally given to somewhat physically more fit patients, whereas bispecific therapy, because you are giving antibody at step-wise dosing in this patient, and you have the ability to stop at any particular dose and then come back and redose, whereas CAR T is, you just give it to them one time, you have a lot more control. So intermediate frail or even frail patients can go through bispecific therapy, whereas it would not be in the best interest of the patient to go through a CAR T-cell therapy when they are frail. So that is another important point. But from the information available, when the patient goes on a BCMA bispecific therapy and they start progressing on treatment, usually it is their T cells are exhausted or the BCMA is no longer expressed on the tumor cells. So coming with CAR T-cell later on is usually not effective, whereas giving CAR T-cell earlier, if the patient relapses later, they have good T-cell function and most of the time the BCMA is still expressed. So you are able to give the BCMA to the maximum benefit by using the CAR T first and BCMA later. So if somebody asked me how to sequence this, just off the bat, you will say CAR T first, BCMA bispecific second. But as I said, there are unique situations. Then there is another potential that is happening. You can change the target. You can use a BCMA against GPRC5D to reduce the tumor, and then go ahead and consolidate it with a CAR T-cell therapy. That is also possible. You are changing the target from GPRC5D to BCMA, the tumor is already down, so the patient is likely to benefit. So these are all newer treatment options which have become available to the physician. So they will have to look at individual patients and decide what is the best course of action for that patient. Dr. Davide Soldato: So, I just wanted to close a little bit with your opinion about how these results translate into clinical practice. So considering this outstanding 5-year data that we have seen, one third of the patients who are alive and progression-free after a single infusion of cilta-cel, do you think that we could start to think about functional cure even in patients who have a diagnosis of relapsed refractory multiple myeloma? Dr. Sundar Jagannath: My feeling is this is important because in this particular study which is published, 12 patients who were followed at Mount Sinai out of the 32 patients who are alive and progression-free, 12 were followed at Mount Sinai. And they were evaluated every year with bone marrow MRD testing by clonoSEQ in 11 of the 12 patients, and one was by multiparametric flow cytometry. So most of them were 10 to the minus 6, not even one in a million cancer cells, and all of them had functional imaging, which is called PET CT every year. So these were patients who had no evidence of disease that we could detect with the technology available today, serologically, in the bone marrow, or anywhere else in the body with a PET CT. They were found to be disease free after a single infusion of cilta-cel. So, that would be almost to the definition of a cure because if you look at cure as a definition for any cancer, cure is defined as a state of complete remission with no trace of cancer that persists over a period of 5 years or longer without maintenance. And that will be applicable for breast cancer, lymphoma, leukemia. So it is a general statement. And if we use that in myeloma too, then I could say that these 12 patients from my center, we proved that they are cured of their myeloma. They are not functionally cured. You've got to remember, there is only cure. That was the definition across all diseases. So there is nothing like a functional cure. They are cured of myeloma. So is myeloma curable? This is the first time we are looking at that. We do know, every physician treating myeloma that there are patients out there, 10 year and beyond, without evidence of disease. This has been published by University of Arkansas, Bart Barlogie's group, who has been saying that myeloma is a curable disease for a long time. And many others have shown long-term follow up. But this one in a late stage disease, we were able to show that they were one treatment with no maintenance. All other studies have been in newly diagnosed myeloma patients. Nobody has shown in late relapse patients on a clinical trial a third of the patient will be progression-free. And 12 of them who were studied were actually disease free. So they were cured of the disease. So if we accept that, then the next question is, first step towards cure is achieving complete remission. They should have no monoclonal protein by any technology you want to use, no measurable residual disease using next gen sequencing or clonoSEQ, and functional imaging whole body PET CT or whole body MRI. So that is important, definition of the complete remission. And then it has to be sustained. That is something the IMWG and IMS, International Myeloma Society, they will have to come together for a consensus. How many years should they be followed and should be in this kind of status with no trace of cancer? Is it, 3 years are enough? 4 years enough? 5 years is enough? For me, I said in this paper, 5 years is a good definition for achieving a potential cure. Then you use the term 'functionally cured'. I have a problem with functionally cured and operationally cured or whatever. Functionally cured was originally put out by Paiva from Spain. There were 8% of newly diagnosed myeloma patients who have, after they go get treated, they will have an MGUS like phenomenon, a small amount of paraprotein detectable, and they are only 8%. And he said that these patients could be off treatment and the disease does not progress. But the problem is when you are giving treatment like maintenance therapy continuously until progression, you do not know exactly who is in the MGUS situation. So you have to have done sophisticated flow cytometry like Paiva did, and it is not quite clinically applicable. So functionally cured applies only for 8% of the people, so it should go out of the vocabulary. Then you can say 'operationally cured'. These are the patients traditionally Bart Barlogie and others showed that they have a large number of patients who have been followed for 10 years with no recurrence of disease, not on treatment. But in those days, they did not have MRD PET CT and all of them done systematically. So that is why they had to come up with a situation where they said they were operationally cured. So yes, myeloma patients have been cured since auto transplant was introduced. I completely agree. It is not new to the CAR T-cell therapy. But the beauty of the CAR T-cell therapy was it was in relapsed refractory myeloma, unmet medical need, number one. Number two, they were studied systematically. It was a clinical trial adjudicated by FDA and EMA for drug approval, cilta-cel was approved. So these patients were carefully followed, and it was a multi-center study. And in that group of patients, we were able to show patients- So, I think this would indicate cure is a reality in myeloma, and as these kind of treatments, immunologic treatment, either it is a CAR T-cell therapy or BCMA bispecific or whatever, there is a chance more patients are likely to be cured, and these treatments have to move forward and so that we are looking towards a cure. That is the beauty of it, and I just thank you for asking and also throwing in this so-called functionally cured, which people like to use casually, and I say it is time to talk more cure and not stuck with functionally cured because that does not allow the field to progress. Dr. Davide Soldato: Thank you very much. That was very interesting. Dr. Sundar Jagannath: And provocative. Dr. Davide Soldato: A little bit, but I think that we needed to close the podcast with this kind of reflection coming from someone who is an expert in the field, as you are. So, I really wanted to thank you for joining us today and for sharing more on your article, which is titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." If you enjoy our show, please leave us a rating and a review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. Dr. Sundar Jagannath: Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Topics covered in this episode: httptap 10 Smart Performance Hacks For Faster Python Code FastRTC Explore Python dependencies with pipdeptree and uv pip tree Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Michael #1: httptap Rich-powered CLI that breaks each HTTP request into DNS, connect, TLS, wait, and transfer phases with waterfall timelines, compact summaries, or metrics-only output. Features Phase-by-phase timing – precise measurements built from httpcore trace hooks (with sane fallbacks when metal-level data is unavailable). All HTTP methods – GET, POST, PUT, PATCH, DELETE, HEAD, OPTIONS with request body support. Request body support – send JSON, XML, or any data inline or from file with automatic Content-Type detection. IPv4/IPv6 aware – the resolver and TLS inspector report both the address and its family. TLS insights – certificate CN, expiry countdown, cipher suite, and protocol version are captured automatically. Multiple output modes – rich waterfall view, compact single-line summaries, or -metrics-only for scripting. JSON export – persist full step data (including redirect chains) for later processing. Extensible – clean Protocol interfaces for DNS, TLS, timing, visualization, and export so you can plug in custom behavior. Example: Brian #2: 10 Smart Performance Hacks For Faster Python Code Dido Grigorov A few from the list Use math functions instead of operators Avoid exception handling in hot loops Use itertools for combinatorial operations - huge speedup Use bisect for sorted list operations - huge speedup Michael #3: FastRTC The Real-Time Communication Library for Python: Turn any python function into a real-time audio and video stream over WebRTC or WebSockets. Features

Today we're digging into the Model Context Protocol, or MCP. Think LSP for AI: build a small Python service once and your tools and data show up across editors and agents like VS Code, Claude Code, and more. My guest, Den Delimarsky from Microsoft, helps build this space and will keep us honest about what's solid versus what's just shiny. We'll keep it practical: transports that actually work, guardrails you can trust, and a tiny server you could ship this week. By the end, you'll have a clear mental model and a path to plug Python into the internet of agents. Episode sponsors Sentry AI Monitoring, Code TALKPYTHON NordStellar Talk Python Courses Links from the show Den Delimarsky: den.dev Agentic AI Programming for Python Course: training.talkpython.fm Model Context Protocol: modelcontextprotocol.io Model Context Protocol Specification (2025-03-26): modelcontextprotocol.io MCP Python Package (PyPI): pypi.org Awesome MCP Servers (punkpeye) GitHub Repo: github.com Visual Studio Code Docs: Copilot MCP Servers: code.visualstudio.com GitHub MCP Server (GitHub repo): github.com GitHub Blog: Meet the GitHub MCP Registry: github.blog MultiViewer App: multiviewer.app GitHub Blog: Spec-driven development with AI (open source toolkit): github.blog Model Context Protocol Registry (GitHub): github.com mcp (GitHub organization): github.com Tailscale: tailscale.com Watch this episode on YouTube: youtube.com Episode #527 deep-dive: talkpython.fm/527 Episode transcripts: talkpython.fm Theme Song: Developer Rap

Topics covered in this episode: The PSF has withdrawn a $1.5 million proposal to US government grant program A Binary Serializer for Pydantic Models T-strings: Python's Fifth String Formatting Technique? Cronboard Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Brian #1: The PSF has withdrawn a $1.5 million proposal to US government grant program Related post from Simon Willison ARS Technica: Python plan to boost software security foiled by Trump admin's anti-DEI rules The Register: Python Foundation goes ride or DEI, rejects government grant with strings attached In Jan 2025, the PSF submitted a proposal for a US NSF grant under the Safety, Security, and Privacy of Open Source Ecosystems program. After months of work by the PSF, the proposal was recommended for funding. If the PSF accepted it, however, they would need to agree to the some terms and conditions, including, affirming that the PSF doesn't support diversity. The restriction wouldn't just be around the security work, but around all activity of the PSF as a whole. And further, that any deemed violation would give the NSF the right to ask for the money back. That just won't work, as the PSF would have already spent the money. The PSF mission statement includes "The mission of the Python Software Foundation is to promote, protect, and advance the Python programming language, and to support and facilitate the growth of a diverse and international community of Python programmers." The money would have obviously been very valuable, but the restrictions are just too unacceptable. The PSF withdrew the proposal. This couldn't have been an easy decision, that was a lot of money, but I think the PSF did the right thing. Michael #2: A Binary Serializer for Pydantic Models 7× Smaller Than JSON A compact binary serializer for Pydantic models that dramatically reduces RAM usage compared to JSON. The library is designed for high-load systems (e.g., Redis caching), where millions of models are stored in memory and every byte matters. It serializes Pydantic models into a minimal binary format and deserializes them back with zero extra metadata overhead. Target Audience: This project is intended for developers working with: high-load APIs in-memory caches (Redis, Memcached) message queues cost-sensitive environments where object size matters Brian #3: T-strings: Python's Fifth String Formatting Technique? Trey Hunner Python 3.14 has t-strings. How do they fit in with the rest of the string story? History percent-style (%) strings - been around for a very long time string.Template - and t.substitute() - from Python 2.4, but I don't think I've ever used them bracket variables and .format() - Since Python 2.6 f-strings - Python 3.6 - Now I feel old. These still seem new to me t-strings - Python 3.14, but a totally different beast. These don't return strings. Trey then covers a problem with f-strings in that the substitution happens at definition time. t-strings have substitution happen later. this is essentially “lazy string interpolation” This still takes a bit to get your head around, but I appreciate Trey taking a whack at the explanation. Michael #4: Cronboard Cronboard is a terminal application that allows you to manage and schedule cronjobs on local and remote servers. With Cronboard, you can easily add, edit, and delete cronjobs, as well as view their status. ✨ Features ✔️ Check cron jobs ✔️ Create cron jobs with validation and human-readable feedback ✔️ Pause and resume cron jobs ✔️ Edit existing cron jobs ✔️ Delete cron jobs ✔️ View formatted last and next run times ✔️ Accepts special expressions like @daily, @yearly, @monthly, etc. ✔️ Connect to servers using SSH, using password or SSH keys ✔️ Choose another user to manage cron jobs if you have the permissions to do so (sudo) Extras Brian: PEP 810: Explicit lazy imports, has been unanimously accepted by steering council Lean TDD book will be written in the open. TOC, some details, and a 10 page introduction are now available. Hoping for the first pass to be complete by the end of the year. I'd love feedback to help make it a great book, and keep it small-ish, on a very limited budget. Joke: You are so wrong!

Today, we're talking about building real AI products with foundation models. Not toy demos, not vibes. We'll get into the boring dashboards that save launches, evals that change your mind, and the shift from analyst to AI app builder. Our guide is Hugo Bowne-Anderson, educator, podcaster, and data scientist, who's been in the trenches from scalable Python to LLM apps. If you care about shipping LLM features without burning the house down, stick around. Episode sponsors Posit NordStellar Talk Python Courses Links from the show Hugo Bowne-Anderson: x.com Vanishing Gradients Podcast: vanishinggradients.fireside.fm Fundamentals of Dask: High Performance Data Science Course: training.talkpython.fm Building LLM Applications for Data Scientists and Software Engineers: maven.com marimo: a next-generation Python notebook: marimo.io DevDocs (Offline aggregated docs): devdocs.io Elgato Stream Deck: elgato.com Sentry's Seer: talkpython.fm The End of Programming as We Know It: oreilly.com LorikeetCX AI Concierge: lorikeetcx.ai Text to SQL & AI Query Generator: text2sql.ai Inverse relationship enthusiasm for AI and traditional projects: oreilly.com Watch this episode on YouTube: youtube.com Episode #526 deep-dive: talkpython.fm/526 Episode transcripts: talkpython.fm Theme Song: Developer Rap